The purported health benefits now appear to be even more far-reaching, with the latest data from a trial called Select, published in 2023, showing that semaglutide can slash the risk of heart attacks and strokes by a fifth in patients with an existing history of cardiovascular disease
Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, Chen X, Zhang B, Liang H, Liu D, et al
But it is documented with other biologic medications, and the mechanism applies to semaglutide as well
This study demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 26% compared with placebo in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors